MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis

Journal of Immunology

Volumn 180, Issue 2, 2008, Pages 1249-1257

  Huan, Jianya ^a,b   Kaler, Laurie J ^a   Mooney, Jeffery L ^b   Subramanian, Sandhya ^a   Hopke, Corwyn ^a   Vandenbark, Arthur A ^a,b   Rosloniec, Edward F ^c   Burrows, Gregory G ^b   Offner, Halina ^a,b,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; COLLAGEN TYPE 2; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT RECEPTOR; RTL2001MII; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; FOXA3 PROTEIN, MOUSE; HEPATOCYTE NUCLEAR FACTOR 3GAMMA; HLA ANTIGEN CLASS 2; HYBRID PROTEIN; I A(Q) BCII257 270 PROTEIN; I-A(Q)-BCII257-270 PROTEIN; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DBA 1 MOUSE; GENE EXPRESSION; HISTOLOGY; IMMUNOMODULATION; JOINT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SPLEEN CELL; T LYMPHOCYTE; ANIMAL; ANTIBODY PRODUCTION; ARTHRITIS; CATTLE; DBA MOUSE; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; REGULATORY T LYMPHOCYTE; SPLEEN; SYNOVIAL FLUID; UPREGULATION;

ANIMALS; ANTIBODY FORMATION; ANTIGENS; ARTHRITIS, EXPERIMENTAL; CATTLE; CYTOKINES; GENE EXPRESSION; HEPATOCYTE NUCLEAR FACTOR 3-GAMMA; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; JOINTS; LIGANDS; MICE; MICE, INBRED DBA; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; SPLEEN; SYNOVIAL FLUID; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 40449142272     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.2.1249     Document Type: Article

References (70)

1. Smolen, J. S., and G. Steiner. 2003. Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov. 2: 473-488.
2. Firestein, G. S. 2003. Evolving concepts of rheumatoid arthritis. Nature 423: 356-361.
3. Goronzy, J. J., and C. M. Weyand. 2005. Rheumatoid arthritis. Immunol. Rev. 204: 55-73.
4. Nepom, G. T. 1998. Major histocompatibility complex-directed susceptibility to rheumatoid arthritis. Adv. Immunol. 68: 315-332.
5. Nepom, G. T. 2001. The role of the DR4 shared epitope in selection and commitment of autoreactive T cells in rheumatoid arthritis. Rheum. Dis. Clin North Am. 27: 305-315.
6. Roudier, J. 2000. Association of MHC and rheumatoid arthritis: association of RA with HLA-DR4: the role of repertoire selection. Arthritis Res. 2: 217-220.
7. Firestein, G. S. 2004. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J. Clin. Invest. 114: 471-474.
8. Sakaguchi, N., T. Takahashi, H. Hata, T. Nomura, T. Tagami, S. Yamazaki, T. Sakihama, T. Matsutani, I. Negishi, S. Nakatsuru, and S. Sakaguchi. 2003. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426: 454-460.
9. Kim, W. U., M. L. Cho, Y. O. Jung, S. Y. Min, S. W. Park, D. J. Min, J. H. Yoon, and H. Y. Kim. 2004. Type II collagen autoimmunity in rheumatoid arthritis. Am. J. Med. Sci. 327: 202-211.
10. Trentham, D. E., R. A. Dynesius, and J. R. David. 1978. Passive transfer by cells of type II collagen-induced arthritis in rats. J. Clin. Invest. 62: 359-366.
11. Holmdahl, R., L. Klareskog, K. Rubin, E. Larsson, and H. Wigzell. 1985. T lymphocytes in collagen II-induced arthritis in mice: characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand. J. Immunol. 22: 295-306.
12. Stuart, J. M., and F. J. Dixon. 1983. Serum transfer of collagen-induced arthritis in mice. J. Exp. Med. 158: 378-392.
13. Holmdahl, R., L. Jansson, A. Larsson, and R. Jonsson. 1990. Arthritis in DBA/1 mice induced with passively transferred type II collagen immune serum: immunohistopathology and serum levels of anti-type II collagen auto-antibodies. Scand. J. Immunol. 31: 147-157.
14. Wooley, P. H., H. S. Luthra, S. K. Singh, A. R. Huse, J. M. Stuart, and C. S. David. 1984. Passive transfer of arthritis to mice by injection of human anti-type II collagen antibody. Mayo Clin. Proc. 59: 737-743.
15. dim mature memory T cells that are potent helpers for B cell differentiation. Arthritis Rheum. 35: 1455-1465.
16. Panayi, G. S., V. M. Corrigall, and C. Pitzalis. 2001. Pathogenesis of rheumatoid arthritis: the role of T cells and other beasts. Rheum. Dis. Clin. North Am. 27: 317-334.
17. Sato, K., A. Suematsu, K. Okamoto, A. Yamaguchi, Y. Morishita, Y. Kadono, S. Tanaka, T. Kodama, S. Akira, Y. Iwakura, et al. 2006. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203: 2673-2682.
18. Rosloniec, E. F., K. B. Whittington, X. He, J. M. Stuart, and A. H. Kang. 2004. Collagen-induced arthritis mediated by HLA-DR1 (*0101) and HLA-DR4 (*0401). Am J. Med. Sci. 327: 169-179.
19. Brand, D. D., A. H. Kang, and E. F. Rosloniec. 2003. Immunopathogenesis of collagen arthritis. Springer Semin. Immunopathol. 25: 3-18.
20. Wooley, P. H. 2004. Immunotherapy in collagen-induced arthritis: past, present, and future. Am. J. Med. Sci. 327: 217-226.
21. Holmdahl, R., R. Bockermann, J. Backlund, and H. Yamada. 2002. The molecular pathogenesis of collagen-induced arthritis in mice: a model for rheumatoid arthritis. Ageing Res. Rev. 1: 135-147.
22. Myers, L. K., H. Miyahara, K. Terato, J. M. Seyer, J. M. Stuart, and A. H. Kang. 1995. Collagen-induced arthritis in B10.RIII mice (H-2r): identification of an arthritogenic T-cell determinant. Immunology 84: 509-513.
23. Wooley, P. H., H. S. Luthra, J. M. Stuart, and C. S. David. 1981. Type II collagen-induced arthritis in mice, I: major histocompatibility complex (I region) linkage and antibody correlates. J. Exp. Med. 154: 688-700.
24. Gregersen, P. K., J. Silver, and R. J. Winchester. 1987. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30: 1205-1213.
25. Winchester, R., E. Dwyer, and S. Rose. 1992. The genetic basis of rheumatoid arthritis: the shared epitope hypothesis. Rheum. Dis. Clin. North Am. 18: 761-783.
26. Michaelsson, E., M. Andersson, A. Engstrom, and R. Holmdahl. 1992. Identification of an immunodominant type-II collagen peptide recognized by T cells in H-2q mice: self tolerance at the level of determinant selection. Eur. J. Immunol. 22: 1819-1825.
27. Brand, D. D., L. K. Myers, K. Terato, K. B. Whittington, J. M. Stuart, A. H. Kang, and E. F. Rosloniec. 1994. Characterization of the T cell determinants in the induction of autoimmune arthritis by bovine α 1(II)-CB11 in H-2q mice. J. Immunol. 152: 3088-3097.
28. Rosloniec, E. F., D. D. Brand, L. K. Myers, K. B. Whittington, M. Gumanovskaya, D. M. Zaller, A. Woods, D. M. Altmann, J. M. Stuart, and A. H. Kang. 1997. An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J. Exp. Med. 185: 1113-1122.
29. Rosloniec, E. F., D. D. Brand, L. K. Myers, Y. Esaki, K. B. Whittington, D. M. Zaller, A. Woods, J. M. Stuart, and A. H. Kang. 1998. Induction of autoimmune arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. J. Immunol. 160: 2573-2578.
30. Rosloniec, E. F., K. B. Whittington, D. M. Zaller, and A. H. Kang. 2002. HLADR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen. J. Immunol. 168: 253-259.
31. Malmstrom, V., J. Backlund, L. Jansson, J. Kihlberg, and R. Holmdahl. 2000. T cells that are naturally tolerant to cartilage-derived type II collagen are involved in the development of collagen-induced arthritis. Arthritis Res. 2: 315-326.
32. Corthay, A., J. Backlund, and R. Holmdahl. 2001. Role of glycopeptide-specific T cells in collagen-induced arthritis: an example how post-translational modification of proteins may be involved in autoimmune disease. Ann. Med. 33: 456-465.
33. Rhode, P. R., M. Burkhardt, J. Jiao, A. H. Siddiqui, G. P. Huang, and H. C. Wong. 1996. Single-chain MHC class II molecules induce T cell activation and apoptosis. J. Immunol. 157: 4885-4891.
34. Appel, H., N. P. Seth, L. Gauthier, and K. W. Wucherpfennig. 2001. Anergy induction by dimeric TCR ligands. J. Immunol. 166: 5279-5285.
35. Nag, B., T. Kendrick, S. Arimilli, S. C. Yu, and S. Sriram. 1996. Soluble MHC II-peptide complexes induce antigen-specific apoptosis in T cells. Cell. Immunol. 170: 25-33.
36. Burrows, G. G., B. F. Bebo, Jr., K. L. Adlard, A. A. Vandenbark, and H. Offner. 1998. Two-domain MHC class II molecules form stable complexes with myelin basic protein 69-89 peptide that detect and inhibit rat encephalitogenic T cells and treat experimental autoimmune encephalomyelitis. J. Immunol. 161: 5987-5996.
37. Burrows, G. G., J. W. Chang, H. P. Bachinger, D. N. Bourdette, H. Offner, and A. A. Vandenbark. 1999. Design, engineering, and production of functional single-chain T cell receptor ligands. Protein Eng. 12: 771-778.
38. Chang, J. W., D. E. Mechling, H. P. Bachinger, and G. G. Burrows. 2001. Design, engineering, and production of human recombinant T cell receptor ligands derived from human leukocyte antigen DR2. J. Biol. Chem. 276: 24170-24176.
39. Huan, J., R. Meza-Romero, J. L. Mooney, Y. Chou, D. M. Edwards, C. Rich, J. M. Link, A. A. Vandenbark, D. N. Bourdette, H.-P. Bachinger, and G. G. Burrows. 2005. Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity. J. Chem. Tech. Biotech. 80: 2-12.
40. Huan, J., S. Subramanian, R. Jones, C. Rich, J. Link, J. Mooney, D. N. Bourdette, A. A. Vandenbark, G. G. Burrows, and H. Offner. 2004. Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch. J. Immunol. 172: 4556-4566.
41. Vandenbark, A. A., C. Rich, J. Mooney, A. Zamora, C. Wang, J. Huan, L. Fugger, H. Offner, R. Jones, and G. G. Burrows. 2003. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. J. Immunol. 171: 127-133.
42. Subramanian, S., M. Tovey, M. Afentoulis, A. Krogstad, A. A. Vandenbark, and H. Offner. 2005. Ethinyl estradiol treats collagen-induced arthritis in DBA/1LacJ mice by inhibiting the production of TNF-α and IL-1β. Clin. Immunol. 115: 162-172.
43. Leung, B. P., N. Sattar, A. Crilly, M. Prach, D. W. McCarey, H. Payne, R. Madhok, C. Campbell, J. A. Gracie, F. Y. Liew, and I. B. McInnes. 2003. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 170: 1524-1530.
44. Burrows, G. G., Y. K. Chou, C. Wang, J. W. Chang, T. P. Finn, N. E. Culbertson, J. Kim, D. N. Bourdette, D. A. Lewinsohn, D. M. Lewinsohn, et al. 2001. Rudimentary TCR signaling triggers default IL-10 secretion by human Th1 cells. J. Immunol. 167: 4386-4395.
45. Dzhambazov, B., K. S. Nandakumar, J. Kihlberg, L. Fugger, R. Holmdahl, and M. Vestberg. 2006. Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J. Immunol. 176: 1525-1533.
46. Offner, H., S. Subramanian, C. Wang, M. Afentoulis, A. A. Vandenbark, J. Huan, and G. G. Burrows. 2005. Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury. J. Immunol. 175: 4103-4111.
47. Wang, C., J. L. Mooney, R. Meza-Romero, Y. K. Chou, J. Huan, A. A. Vandenbark, H. Offner, and G. G. Burrows. 2003. Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation. J. Immunol. 171: 1934-1940.
48. - T cells. J. Clin. Invest. 112: 1437-1443.
49. Rosloniec, E. F., K. B. Whittington, D. D. Brand, L. K. Myers, and J. M. Stuart. 1996. Identification of MHC class II and TCR binding residues in the type II collagen immunodominant determinant mediating collagen-induced arthritis. Cell. Immunol. 172: 21-28.
50. Kjellen, P., U. Brunsberg, J. Broddefalk, B. Hansen, M. Vestberg, I. Ivarsson, A. Engstrom, A. Svejgaard, J. Kihlberg, L. Fugger, and R. Holmdahl. 1998. The structural basis of MHC control of collagen-induced arthritis: binding of the immunodominant type II collagen 256-270 glycopeptide to H-2Aq and H-2Ap molecules. Eur. J. Immunol. 28: 755-767.
51. Backlund, J., A. Treschow, R. Bockermann, B. Holm, L. Holm, S. Issazadeh-Navikas, J. Kihlberg, and R. Holmdahl. 2002. Glycosylation of type II collagen is of major importance for T cell tolerance and pathology in collagen-induced arthritis. Eur. J. Immunol. 32: 3776-3784.
52. Huseby, E. S., F. Crawford, J. White, P. Marrack, and J. W. Kappler. 2006. Interface-disrupting amino acids establish specificity between T cell receptors and complexes of major histocompatibility complex and peptide. Nat. Immunol. 7: 1191-1199.
53. Iwakura, Y., and H. Ishigame. 2006. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116: 1218-1222.
54. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
55. Cho, M. L., J. W. Kang, Y. M. Moon, H. J. Nam, J. Y. Jhun, S. B. Heo, H. T. Jin, S. Y. Min, J. H. Ju, K. S. Park, et al. 2006. STAT3 and NF-κB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J. Immunol. 176: 5652-5661.
56. Murphy, C. A., C. L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R. A. Kastelein, J. D. Sedgwick, and D. J. Cua. 2003. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198: 1951-1957.
57. Chen, Y., C. L. Langrish, B. McKenzie, B. Joyce-Shaikh, J. S. Stumhofer, T. McClanahan, W. Blumenschein, T. Churakovsa, J. Low, L. Presta, et al. 2006. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 116: 1317-1326.
58. McKenzie, B. S., R. A. Kastelein, and D. J. Cua. 2006. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 27: 17-23.
59. Dong, C. 2006. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat. Rev. Immunol. 6: 329-333.
60. Hoeve, M. A., N. D. Savage, T. de Boer, D. M. Langenberg, R. de Waal Malefyt, T. H. Ottenhoff, and F. A. Verreck. 2006. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur. J. Immunol. 36: 661-670.
61. Weaver, C. T., L. E. Harrington, P. R. Mangan, M. Gavrieli, and K. M. Murphy. 2006. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24: 677-688.
62. Acosta-Rodriguez, E. V., G. Napolitani, A. Lanzavecchia, and F. Sallusto. 2007. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8: 942-949.
63. Sakaguchi, S., K. Fukuma, K. Kuribayashi, and T. Masuda. 1985. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset, I: evidence for the active participation of T cells in natural self-tolerance, deficit of a T cell subset as a possible cause of autoimmune disease. J. Exp. Med. 161: 72-87.
64. + suppressor T cells. J. Exp. Med. 193: F41-F46.
65. Akdis, M., J. Verhagen, A. Taylor, F. Karamloo, C. Karagiannidis, R. Crameri, S. Thunberg, G. Deniz, R. Valenta, H. Fiebig, et al. 2004. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J. Exp. Med. 199: 1567-1575.
66. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10: 1969-1980.
67. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188: 287-296.
68. + immunoregulatory T cells is antigen nonspecific. J. Immunol. 164: 183-190.
69. + T cells by regulatory T cells during persistent retroviral infection. Immunity 20: 293-303.
70. - cells. Proc. Natl. Acad. Sci. USA 102: 4103-4108.